0.47 USD
▼-0.05-9.27%
盘后 0.38 -19.15%
2026-10-22
市值
$1.48M
市盈率
—
EPS
-1.06
股息率
—
52 周区间
0.46 – 13.28
成交量
174.31K
Beta
0.35
目标价
—
52W 低 0.4652W 高 13.28
价格走势
公司简介
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and vali...